Comparative Pharmacology
Head-to-head clinical analysis: AJOVY versus MYZILRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AJOVY versus MYZILRA.
AJOVY vs MYZILRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ajovy (fremanezumab) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated neurogenic vasodilation and pain transmission in trigeminal sensory neurons.
MYZILRA is a monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing IgG recycling and lowering circulating IgG levels, including pathogenic autoantibodies.
AJOVY (fremanezumab-vfrm) is administered subcutaneously at a dose of 675 mg once every 3 months (quarterly) or 225 mg once monthly. The injection volume is 1.5 mL for the 225 mg dose and 4.5 mL for the 675 mg dose, administered as three separate injections of 225 mg each.
10 mg intravenously once daily for 12 weeks, followed by 10 mg subcutaneously every 8 weeks for maintenance.
None Documented
None Documented
Terminal elimination half-life is 31 days (range 23-37 days). This long half-life supports monthly subcutaneous dosing.
Terminal elimination half-life is 22 hours; permits once-daily dosing in most patients.
Renal excretion of intact antibody is minimal; metabolized via catabolism to peptides and amino acids. Approximately 100% of elimination is via intracellular degradation (proteolysis) and biliary excretion of metabolites, with negligible renal excretion.
Renal elimination of unchanged drug accounts for 70% of clearance; biliary/fecal excretion accounts for 25%; 5% metabolized.
Category C
Category C
CGRP Antagonist
CGRP Antagonist